Clinical study of operation combined with ¹²⁵I seeds implantation in the treatment of recurrent cerebral glioma

Objective: To explore the therapeutic effect and complications of operation combined with ¹²⁵I seeds implantation in the treatment of brain glioma. Methods: A retrospective analysis was underwent in 58 cases of recurrent cerebral glioma patients, among them, 23 patients were treated with simple operation, 35 cases were given treatment plans by three-dimensional treatment planning system in preoperation or intraoperation, and according to the does set in intraoperation, ¹²⁵I seeds were implanted in the tumor bed after tumor resection with the prescription dose was 140-188 Gy. Verification and quality evaluation was performed every 2 months by CT or MRI. After 8-32 months follow-up, tumor recurrence rate, survival time and complications were compared between the two groups. Results: There were 20 cases of recurrence in the simple operation group and the recurrence rate was 87%, 3 patients died of postoperative complications. There were 23 cases of recurrence in the intraoperative ¹²⁵I seeds implantation group and the recurrence rate was 65.7%; 5 patients died of postoperative complications, 4 cases of refractory cerebral edema, 3 cases of radiation necrosis of the brain. The recurrence time in intraoperative ¹²⁵I implantation group [(97.5 ± 15.3) weeks] was significantly greater than that in simple operation group [(62.5 ± 13.6) weeks] (t = 9.21, P < 0.05), the survival time [(60.3 ± 7.1) weeks] was significantly longer than that in simple operation group [(43.1 ± 5.5) weeks] (t = 13.03, P < 0.05). Conclusion: ¹²⁵I seeds implantation treatment intraoperative could reduce glioma recurrence rate, effectively improve the survival time in recurrent glioma patients. (authors)